Drug Profile
Research programme: anticancer antibodies - ARCA biopharma
Alternative Names: IREM-1-antagonists; NTB-A; NTB-A-antagonists; NU 10458; NU 2444; NUVO 13759; NUVO 14453; NUVO 16587; NUVO 17289; NUVO 18778; NUVO 18832; NUVO 2788Latest Information Update: 04 Oct 2012
Price :
$50
*
At a glance
- Originator
- Developer ARCA biopharma Inc
- Class Monoclonal antibodies
- Mechanism of Action C-type lectin-like molecule-1 protein inhibitors; CD150 antigen inhibitors; CD300LF protein antagonists; Complement activation stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Leukaemia
Most Recent Events
- 04 Oct 2012 Discontinued - Preclinical for Leukaemia in USA (Parenteral)
- 28 Jan 2009 Nuvelo has merged with ARCA biopharma to form ARCA biopharma Inc
- 28 Aug 2003 Preclinical trials in Cancer in USA (unspecified route)